Ventas Inc News

Ventas Analyst Ratings

BenzingaMar 18 05:59 ET

Omega Healthcare, National Health Investors Upgraded to Overweight at Wells Fargo

Seeking AlphaFeb 26 10:05 ET

Ventas Analyst Ratings

BenzingaFeb 26 06:41 ET

Ventas Analyst Ratings

BenzingaJan 30 07:06 ET

Ventas Analyst Ratings

BenzingaJan 16 12:15 ET

BofA Upgrades Ventas to Buy From Neutral on External Growth Opportunities, Adjusts Price Target to $53 From $48

MT NewswiresJan 16 11:16 ET

Mizuho Maintains Buy on Ventas, Raises Price Target to $56

BenzingaJan 3 10:40 ET

Ventas Analyst Ratings

BenzingaJan 3 10:39 ET

RBC Trims Price Target on Ventas to $52 From $53, Keeps Outperform Rating

MT NewswiresNov 28, 2023 07:11 ET

Wells Fargo Maintains Overweight on Ventas, Lowers Price Target to $47

BenzingaNov 13, 2023 10:12 ET

Ventas Analyst Ratings

BenzingaNov 13, 2023 10:11 ET

Wells Fargo Sticks to Its Buy Rating for Ventas (VTR)

TipRanksNov 13, 2023 07:18 ET

Wedbush Upgrades Ventas to Outperform, Raises Price Target to $51

BenzingaNov 7, 2023 07:20 ET

Ventas Analyst Ratings

BenzingaNov 7, 2023 07:19 ET

Ventas Analyst Ratings

BenzingaOct 11, 2023 12:41 ET

BNP Paribas Starts Coverage on Ventas With Outperform Rating, $47 Price Target

MT NewswiresOct 11, 2023 09:18 ET

Wedbush Initiates Coverage On Ventas With Neutral Rating, Announces Price Target of $44

BenzingaOct 3, 2023 08:02 ET

Ventas Analyst Ratings

BenzingaOct 3, 2023 08:01 ET

Ventas Analyst Ratings

BenzingaSep 22, 2023 09:41 ET

BMO Capital Adjusts Ventas Price Target to $51 From $52, Maintains Outperform Rating

MT NewswiresSep 22, 2023 09:02 ET